Dopamine receptor contribution to the action of PCP, LSD and ketamine psychotomimetics
The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
Although phencyclidine and ketamine are used to model a hypoglutamate theory of schizophrenia, their selectivity for NMDA receptors has been questioned. To determine the affinities of phencyclidine, ketamine, dizocilpine and LSD for the functional high-affinity state of the dopamine D2 receptor, D2High, their dissociation constants (Ki) were obtained on [3H]domperidone binding to human cloned dopamine D2 receptors. Phencyclidine had a high affinity for D2High with a Ki of 2.7 nM, in contrast to its low affinity for the NMDA receptor, with a Ki of 313 nM, as labeled by [3H]dizocilpine on rat striatal tissue. Ketamine also had a high affinity for D2High with a Ki of 55 nM, an affinity higher than its 3100 nM Ki for the NMDA sites. Dizocilpine had a Ki of 0.3 nM at D2High, but a Kd of 1.8 nM at the NMDA receptor. LSD had a Ki of 2 nM at D2High. Because the psychotomimetics had higher potency at D2High than at the NMDA site, the psychotomimetic action of these drugs must have a major contribution from D2 agonism. Because these drugs have a combined action on both dopamine receptors and NMDA receptors, these drugs, when given in vivo, test a combined hyperdopamine and hypoglutamate theory of psychosis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“a set of studies observed a high affinity of ketamine for the human D2 receptor expressed in Chinese Hamster Ovary cells (0.5 μM, Ki = 55 μM) and rat striatal 5-HT2 receptor (15 μM) (Kapur & Seeman, 2002; Seeman et al., 2005).”
From Mechanisms of ketamine and its metabolites as antidepressants (2022) · cites this paper as Seeman et al., 2005
Citations
Cites
Recent advances in the phencyclidine model of schizophrenia
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.10.1301 · Cited by 2,904
Jentsch, J. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00060-8 · Cited by 1,314
The Emerging Role of Glutamate in the Pathophysiology and Treatment of Schizophrenia
Goff, D. C., & Coyle, J. T. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.9.1367 · Cited by 915
Atypical antipsychotics: Mechanism of action
Seeman, P. (2002) · The Canadian Journal of Psychiatry · doi:10.1177/070674370204700106 · Cited by 899
Self-citationDopamine receptors and the dopamine hypothesis of schizophrenia
Seeman, P. (1987) · Synapse · doi:10.1002/syn.890010203 · Cited by 880
Self-citationLee, F. J. S., Xue, S., Pei, L., Vukusic, B., Chéry, N., Wang, Y., Wang, Y. T., Niznik, H. B., Yu, X.-M., & Liu, F. (2002) · Cell · doi:10.1016/s0092-8674(02)00962-5 · Cited by 542
Köhler, C., Hall, H., Ögren, S.-O., & Gawell, L. (1985) · Biochemical Pharmacology · doi:10.1016/0006-2952(85)90778-6 · Cited by 505
Kapur, S., & Seeman, P. (2002) · Molecular Psychiatry · doi:10.1038/sj.mp.4001093 · Cited by 459
Self-citationInteractive effects of subanesthetic ketamine and haloperidol in healthy humans
Krystal, J. H., D'Souza, D. C., Karper, L. P., Bennett, A., Abi-Dargham, A., Abi-Saab, D., Cassello, K., Bowers Jr., M. B., Vegso, S., Heninger, G. R., et al. (1999) · Psychopharmacology · doi:10.1007/s002130051049 · Cited by 243
Regulation of Dopamine D1 Receptor Function by Physical Interaction with the NMDA Receptors
Pei, L., Lee, F. J. S., Moszczynska, A., Vukusic, B., & Liu, F. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.3922-03.2004 · Cited by 209
Research works printed but not linked: 1
- Van Rossum JM . The significance of dopamine-receptor blockade for the action of neuroleptic drugs. In: Brill H, Cole J, Deniker P, Hippius H, Bradley PB (eds). Neuropsychopharmacology, Proceedings of the 5th Collegium Internationale Neuropsychopharmacologicum. Excerpta Medica Foundation: Amsterdam, 1967, pp 321–329.
Cited by
Items 101–200 of 200
Chen, Y.-C., & Holmes, A. (2008) · Neuropsychopharmacology · doi:10.1038/npp.2008.182 · Cited by 25
“While MK-801 effects targets other than the NMDAR, including dopamine (Seeman et al., 2005), norepinephrine (Snell et al.”
Rizzo, A., Garçon-Poca, M. Z., Essmann, A., Souza, A. J., Michaelides, M., Ciruela, F., & Bonaventura, J. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-02931-3 · Cited by 25
“Some studies have suggested direct interactions with monoamine transporters [16, 17] or pre-synaptic receptors [18, 19].”
Cholinergic Neurons of the Medial Septum Are Crucial for Sensorimotor Gating
Jin, J., Cheng, J., Lee, K.-W., Amreen, B., McCabe, K. A., Pitcher, C., Liebmann, T., Greengard, P., & Flajolet, M. (2019) · Journal of Neuroscience · doi:10.1523/jneurosci.0950-18.2019 · Cited by 24
“…molecular targets (e.g., dopamine and se- rotonin receptors and transporters, nicotine acetylcholine 7 receptors; Ramoa et al., 1990; Clarke and Reuben, 1995; Iravani et al., 1999; Seeman et al., 2005) more work will be needed to elucidate these alternative pathways and their possible contribution.”
BackgroundBehavioral effects of prenatal ketamine exposure in rhesus macaques are dependent on MAOA genotype.
Capitanio, J. P., Rosso, L. A. D., Calonder, L. A., Blozis, S. A., & Penedo, M. C. T. (2012) · Experimental and Clinical Psychopharmacology · doi:10.1037/a0026773 · Cited by 20
Phencyclidine Discoordinates Hippocampal Network Activity But Not Place Fields
Kao, H.-Y., Dvořák, D., Park, E., Kenney, J., Kelemen, E., & Fenton, A. A. (2017) · Journal of Neuroscience · doi:10.1523/jneurosci.0630-17.2017 · Cited by 21
“Although blocking NMDARs reduces excitation, it is unclear whether PCP’s consequences arise from hypo- or hyperglutaminergic effects (Adams and Moghaddam, 1998; Seeman et al., 2005; Sershen et al., 2008).”
BackgroundRapid Antidepressant Activity of Ketamine Beyond NMDA Receptor
Hashimoto, K. (2017) · Springer eBooks · doi:10.1007/978-3-319-49795-2_4 · Cited by 17
Ketamine plus Alcohol: What We Know and What We Can Expect about This
Kobayashi, N. H. C., Farias, S. V., Luz, D. A., Ferraro, K. M. M. M., da Conceição, B. C., da Silveira, C. C. S. D. M., Fernandes, L. M. P., Cartágenes, S. D. C., Ferreira, V. M. M., Fontes-Júnior, E. A., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23147800 · Cited by 19
Minuzzi, L., & Cumming, P. (2010) · Neurochemistry International · doi:10.1016/j.neuint.2010.01.010 · Cited by 15
The versatile binding landscape of the TAAR1 pocket for LSD and other antipsychotic drug molecules
Jiang, K., Zheng, Y. Y., Zeng, L., Wang, L., Li, F., Pu, J., Lu, Y., Zhao, S., & Xu, F. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114505 · Cited by 15
Agatsuma, S., Dang, M. T., Li, Y., & Hiroi, N. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.12.023 · Cited by 15
“However, this antagonist also increases glutamate release (3) and binds to the dopamine D2 receptor (4).”
Assessment of the rapid and sustained antidepressant-like effects of dextromethorphan in mice
Saavedra, J. S., Garrett, P. I., Honeycutt, S. C., Peterson, A. M., White, J., & Hillhouse, T. M. (2020) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2020.173003 · Cited by 15
Ketamine induces hyperactivity in rats and hypersensitivity to nicotine in rat striatal slices
Rodvelt, K. R., Kracke, G. R., Schachtman, T. R., & Miller, D. K. (2008) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2008.06.012 · Cited by 12
Takagi, S., Balu, D. T., & Coyle, J. T. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2014.12.034 · Cited by 12
“…has a favorable profile because it has an extremely high (10–100 fold higher than PCP and ketamine) affinity to (Kornhuber and Weller, 1997), and a high selectivity for the PCP binding site of the NMDAR (Wong et al., 1986) whereas PCP also binds to the dopamine D2 receptor (Seeman et al., 2005).”
Jiang, Y., Dong, Y., & Hu, H. (2024) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2023.0225 · Cited by 15
“However, departing from early assessments [106,117,118], a recent study, using a G protein-coupled receptor (GPCR)-based functional binding assay, revealed that ketamine does not interact with D2Rs under treatment-relevant dosage [166].”
BackgroundResultInfluentialAdams, W. K., Halberstadt, A. L., & van den Buuse, M. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00109 · Cited by 10
“Like other reports (Snell et al., 1988; Hiramatsu et al., 1989; Rothman, 1994; Kapur and Seeman, 2002; Seeman et al., 2005; Seeman and Lasaga, 2005), our findings lend strength to the notion that the schizophrenomimetic effects of PCP and ketamine may not be due to NMDA receptor antagonism alone.”
BackgroundResultNeves, G. A., Borsoï, M., Antonio, C. B., Pranke, M. A., Betti, A. H., & Rates, S. M. K. (2017) · Anais da Academia Brasileira de Ciências · doi:10.1590/0001-3765201720160844 · Cited by 13
Lin, H., Kim, J. G., Park, S. W., Noh, H. J., Kim, J., Yoon, C. Y., Woo, N.-S., Kim, B., Cho, S., Choi, B. H., et al. (2018) · Experimental & Molecular Medicine · doi:10.1038/s12276-018-0073-6 · Cited by 12
Strickley, T., Smith, K., & Ericksen, A. M. (2023) · Journal of PeriAnesthesia Nursing · doi:10.1016/j.jopan.2023.08.003 · Cited by 10
Preliminary studies of 99mTc-memantine derivatives for NMDA receptor imaging
Zhou, X., Zhang, J., Yan, C.-L., Cao, G., Zhang, R., Cai, G., Jiang, M.-J., & Songpei, W. (2012) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2012.02.008 · Cited by 9
“15×10−8mol/l, respectively, which are the same order of magnitude as previously reported values (3100 nM and 79 nM, respectively) [35,36].”
BackgroundNona, C. N., & Nóbrega, J. N. (2017) · Behavioural Brain Research · doi:10.1016/j.bbr.2017.09.024 · Cited by 12
“Furthermore, MK-801 is known to bind not only to activated NMDARs, but also to acetylcholine [52] and dopamine [53] receptors, while also having its own sensitization-producing effects [54].”
Phencyclidine Disrupts Neural Coordination and Cognitive Control by Dysregulating Translation
Park, E., Kao, H., Jourdi, H., van Dijk, M. T., Segura-Carrillo, S., Tunnell, K. W., Gutierrez, J., Wallace, E. J. C., Regier, M., Radwan, B., et al. (2023) · Biological Psychiatry Global Open Science · doi:10.1016/j.bpsgos.2023.04.009 · Cited by 9
“https://doi.org/10.1016/j.bpsgos.2023.04.009 Phencyclidine (PCP) is a potent uncompetitive antagonist of glutamatergic NMDA receptors (NMDARs) (1,2) with dopamine-mimetic effects at dopamine D 2 receptors (3 – 5).”
BackgroundInfluentialBiological Perspectives: The Role of Glutamate in Schizophrenia and Its Treatment
Steele, D., Moore, R. L., Swan, N. A., Grant, J. S., & Keltner, N. L. (2012) · Perspectives In Psychiatric Care · doi:10.1111/j.1744-6163.2012.00333.x · Cited by 10
Do Dopamine Receptors Mediate Part of MAC?
Tanifuji, Y., Zhang, Y., Liao, M. Y., Eger, E. I., Laster, M. J., & Sonner, J. M. (2006) · Anesthesia & Analgesia · doi:10.1213/01.ane.0000244334.52163.a3 · Cited by 8
“But MK-801 is a “dirty” blocker, potently affecting other receptors, particularly dopamine (9).”
BackgroundFibromyalgia as a Disorder Related to Distress and its Therapeutic Implications
Schweinhardt, P., Fitzcharles, M., Boomershine, C. S., Vierck, C. J., & Yunus, M. B. (2012) · Pain Research and Treatment · doi:10.1155/2012/950602 · Cited by 8
Behavioral effects associated with chronic ketamine or remacemide exposure in rats
Wright, L. K. M., Pearson, E. C., Hammond, T. G., & Paule, M. G. (2007) · Neurotoxicology and Teratology · doi:10.1016/j.ntt.2006.12.004 · Cited by 7
Haloperidol for the Treatment of Ketamine-Indu ced Emergence Delirium
Atlas, G. M., & Milles, M. (2007) · Journal of Anaesthesiology Clinical Pharmacology · Cited by 6
Andrews, J. L., Newell, K. A., Matosin, N., Huang, X., & Fernandez, F. (2015) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2015.06.003 · Cited by 6
Acute and subchronic PCP attenuate D2 autoreceptor signaling in substantia nigra dopamine neurons
Piccart, E., Tschumi, C. W., & Beckstead, M. J. (2019) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2019.01.108 · Cited by 6
“In vitro, PCP has been reported to display agonist action of D2 receptors in their high-affinity state (Kapur and Seeman, 2002; Seeman and Guan, 2008; Seeman et al., 2005), to inhibit the dopamine uptake transporter (DAT; Schiffer et al.”
BackgroundKovacova, V., Macejova, A., Tonhajzerová, I., Višňovcová, Z., Ferencová, N., Mlyncekova, Z., Kukucka, T., Farský, I., Nosáľ, S., & Ondrejka, I. (2024) · Pharmaceuticals · doi:10.3390/ph17030358 · Cited by 7
Animal Models and Hallucinogenic Drugs
Kozlenkov, A., & González‐Maeso, J. (2012) · Springer eBooks · doi:10.1007/978-1-4614-4121-2_14 · Cited by 6
Fernandez, F. (2015) · Journal of Pharmaceutics & Pharmacology · doi:10.13188/2327-204x.1000013 · Cited by 3
“Phencyclidine or 1-(1-phenylcyclohexyl) piperidine (also known as PCP) is a potent non-competitive NMDA receptor antagonist [2-4].”
BackgroundAllen, R. M. (2013) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2013.09.005 · Cited by 4
“In addition to effects at the NMDAR, there is some evidence that dizocilpine can bind with high affinity to the high affinity state of the dopamine D2 receptor (Seeman et al., 2005).”
BackgroundGlutamate Pharmacological Models Relevant to Schizophrenia and Psychosis
Rafter, M. D., Fone, K. C. F., & Moran, P. M. (2015) · Handbook of behavioral neuroscience · doi:10.1016/b978-0-12-800981-9.00010-9 · Cited by 5
Ketamine in treatment-resistant depression
Lapidus, K. A. B., & Mathew, S. J. (2013) · Cambridge University Press eBooks · doi:10.1017/cbo9781139175869.027 · Cited by 4
Pickering, C. (2010) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2010.00032 · Cited by 5
Andrews, J. L., Newell, K. A., Matosin, N., Huang, X., & Fernandez, F. (2018) · Neuronal Signaling · doi:10.1042/ns20180059 · Cited by 5
Chapp, A. D., Huber, M. J., Collins, A. R., Driscoll, K. M., Behnke, J. E., Larson, R. A., Shan, Z. J., Zhang, L., & Chen, Q. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.07.20.212597 · Cited by 4
Functional reactivity of the dopaminergic system following acute and chronic ketamine treatments
Owolabi, R. A., Akanmu, M. A., & Ukponmwan, O. E. (2008) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-008-0283-x · Cited by 3
“This was supported by ligand binding studies which reported higher affinity of NMDA receptor antagonists (ketamine and phencyclidine) for the postsynaptic D2 receptor relative to the NMDA receptor, hence, their observed effect on dopaminergic transmission was suggested to result from postsynaptic D2 agonism (Seeman et…”
BackgroundResultInfluentialAssessing suicide risk in chronic pain management: a narrative review across drug classes
Brezić, N., Gligorevic, S., Candido, K. D., & Knežević, N. N. (2024) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2024.2391999 · Cited by 2
Herrington, J. A., Rosso, L. A. D., & Capitanio, J. P. (2019) · Developmental Psychobiology · doi:10.1002/dev.21843 · Cited by 3
Kétamine et douleur chronique en France : de la théorie à la pratique
Morel, V., & Pickering, G. P. (2021) · Douleur et Analgésie · doi:10.3166/dea-2021-0155 · Cited by 2
Exercise against cocaine sensitization in mice: a [18F]fallypride micro-PET study
Becker, G., Lespine, L., Bahri, M. A., Navacerrada, M. E. S., Lemaire, C. F., Luxen, A., Tirelli, E., & Plenevaux, A. (2021) · Brain Communications · doi:10.1093/braincomms/fcab294 · Cited by 4
“changed total amount of receptors (low and high-affinity states).(36,37)”
BackgroundRamírez-Paesano, C. R., Clarens, C. R., Segovia, A. S., Bustinza, A. C., Olive, J. R., & Galceran, A. J. (2023) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-023-02829-9 · Cited by 3
“Acute administration of ketamine increases dopamine levels in the frontal cortex, striatum, and nucleus accumbens, and the unpleasant side effects of ketamine are generally thought to be mediated by its agonistic effect on dopamine DA-2 receptors [40].”
BackgroundShen, A. N., & Newland, M. C. (2015) · Psychopharmacology · doi:10.1007/s00213-015-4120-x · Cited by 2
Kokkinou, M., Irvine, E. E., Bonsall, D. R., Natesan, S., Wells, L. A., Smith, M., Glegola, J. A., Paul, E. J., Tossell, K., Veronese, M., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/748665 · Cited by 2
“Proposed mechanism of action of ketamine on dopamine synthesis capacity Ketamine is a non-competitive NMDAR antagonist that binds with high affinity Ki= 3.1 μM to the same binding site as MK801 and PCP (44–46).”
BackgroundInfluentialAnderson, D., Hinchcliffe, J. K., Jackson, M. G., & Robinson, E. S. J. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.10.25.684561 · Cited by 2
Roger, R. D., & Whittington, M. A. (2010) · Oxford University Press eBooks · doi:10.1093/acprof:oso/9780195342796.003.0011 · Cited by 1
Čampara, A., & Kovačić, D. (2024) · World Congress on Medical Physics and Biomedical Engineering, September 7 - 12, 2009, Munich, Germany · doi:10.1007/978-3-031-49068-2_54 · Cited by 1
Dahleh, M. M. M., Müller, S. G., Klann, I. P., Marques, L. S., Rosa, J., Fontoura, M. B., Bürger, M. E., Nogueira, C. W., Prigol, M., Boeira, S. P., et al. (2024) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2024.111238 · Cited by 1
Sapp, C., Rich, M. E., Hess, K., Losco, A., Zupancic, A., & Caldwell, H. K. (2025) · Neuropharmacology · doi:10.1016/j.neuropharm.2025.110442 · Cited by 1
“Because PCP is a weak NMDA receptor antagonist and strong dopamine D 2 receptor agonist (Seeman et al., 2005), it has construct validity as a schizophrenia model.”
Hunt, M. J., & Wróbel, J. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811251352454 · Cited by 1
“The psychotomimetics ketamine, phencyclidine, and MK801 have a high potency at D2 receptors (Kapur and Seeman, 2002; Seeman et al., 2005).”
La‐Torraca‐Vittori, P., Tarchi, L., Arrigo, E., Lanterna, S., Tosi, E., Doose, A., Palesi, F., Pischedda, D., Ricca, V., Fusar‐Poli, P., et al. (2025) · European Journal of Neuroscience · doi:10.1111/ejn.70338 · Cited by 2
“…the existing literature on LSD (Canal and Murnane 2017; Halberstadt and Geyer 2011; Moreno et al. 2011; Passie et al. 2008; Perry and Perry 1995; Seeman et al. 2005) and the available receptor maps at the time of study conduction, the following spatial features were retrieved from neuromaps :…”
Ketamine for post-thoracotomy pain: An old drug with new horizons
Gupta, N., & Dattatri, R. (2019) · Indian Journal of Cancer · doi:10.4103/ijc.ijc_18_19 · Cited by 1
Diverse pharmacological properties of ketamine
Laher, I., Zhang, X., Leung, P. C., & Liang, W. (2015) · CRC Press eBooks · doi:10.1201/b18230-4 · Cited by 1
Bærentzen, S. L., Thomsen, J. B., Thomsen, M. B., Jakobsen, S., Simonsen, M. I. T., Wegener, G., Brooks, D. J., & Landau, A. M. (2024) · Synapse · doi:10.1002/syn.22294 · Cited by 1
Ketamine and the Dissociatives
Frohlich, J., & Horn, J. D. V. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-800212-4.00060-1 · Cited by 2
Phencyclidine and Phencyclidine Analogues
Barceloux, D. G. (2012) · doi:10.1002/9781118105955.ch34 · Cited by 1
Roger, R. D., & Whittington, M. A. (2010) · Oxford University Press eBooks · doi:10.1093/acprof:oso/9780195342796.003.0012 · Cited by 1
Kotermanski, S. E. (2008) · D-Scholarship@Pitt (University of Pittsburgh)
Assessment of Dopamine and Serotonin Release in the Non-Human Primate Brain using PET
Finnema, S. J. (2011) · Figshare
Pyrrole analogues of Phencyclidine decrease food and water consumption in mice
Solati, J., Ahmadi, A. N., Pakzad, S., & Salari, A. (2011) · Neurochemical Journal · doi:10.1134/s1819712411040167
Specific modalities of treatment
McGrath, P. J., & Roose, S. P. (2013) · Cambridge University Press eBooks · doi:10.1017/cbo9781139175869.024
Cortical Neurons and Their Models
Roger, R. D., & Whittington, M. A. (2010) · Oxford University Press eBooks · doi:10.1093/acprof:oso/9780195342796.003.0008
Epileptiform Discharges In Vitro
Roger, R. D., & Whittington, M. A. (2010) · Oxford University Press eBooks · doi:10.1093/acprof:oso/9780195342796.003.0013
Gap Junctions and the Notion of Electrical Coupling Between Axons
Roger, R. D., & Whittington, M. A. (2010) · Oxford University Press eBooks · doi:10.1093/acprof:oso/9780195342796.003.0009
Overview of In Vivo Cortical Oscillations
Roger, R. D., & Whittington, M. A. (2010) · Oxford University Press eBooks · doi:10.1093/acprof:oso/9780195342796.003.0003
Roger, R. D., & Whittington, M. A. (2010) · Oxford University Press eBooks · doi:10.1093/acprof:oso/9780195342796.003.0010
Seeman, P. M., Caruso, C. M., & Lasaga, M. (2008)
Self-citationDiverse pharmacological properties of ketamine
Laher, X. Z. I., Zhang, X., Chung, L. P., & Liang, W. (2015) · CRC Press eBooks · doi:10.1201/b18230-7
Lawford‐Smith, H. (2015)
Substances of Abuse and Hallucinogenic Activity: The Glutamatergic Pathway - Focus on Ketamine
Mandolini, G. M., Lazzaretti, M., Altamura, A. C., & Brambilla, P. (2018) · Springer eBooks · doi:10.1007/978-3-319-75124-5_3
(2008) · CRC Press eBooks · doi:10.1201/9780849378812.ch4
Martins, Y. C. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00153-5
Roger, R. D., & Whittington, M. A. (2010) · Oxford University Press eBooks · doi:10.1093/acprof:oso/9780195342796.003.0005
Roger, R. D., & Whittington, M. A. (2010) · Oxford University Press eBooks · doi:10.1093/acprof:oso/9780195342796.003.0001
Roger, R. D., & Whittington, M. A. (2010) · Oxford University Press eBooks · doi:10.1093/acprof:oso/9780195342796.003.0006
Roger, R. D., & Whittington, M. A. (2010) · Oxford University Press eBooks · doi:10.1093/acprof:oso/9780195342796.003.0004
Roger, R. D., & Whittington, M. A. (2010) · Oxford University Press eBooks · doi:10.1093/acprof:oso/9780195342796.003.0014
Roger, R. D., & Whittington, M. A. (2010) · Oxford University Press eBooks · doi:10.1093/acprof:oso/9780195342796.003.0002
Roger, R. D., & Whittington, M. A. (2010) · Oxford University Press eBooks · doi:10.1093/acprof:oso/9780195342796.003.0007
(2010) · Oxford University Press eBooks · doi:10.1093/acprof:oso/9780195342796.002.0004
(2010) · Oxford University Press eBooks · doi:10.1093/acprof:oso/9780195342796.002.0006
(2010) · Oxford University Press eBooks · doi:10.1093/acprof:oso/9780195342796.002.0005
(2010) · Oxford University Press eBooks · doi:10.1093/acprof:oso/9780195342796.002.0009
Intérêt de la kétamine dans le traitement des douleurs chroniques
Pickering, G. P. (2023) · Biologie Aujourd hui · doi:10.1051/jbio/2023019 · Cited by 1
Ketamine’s Multifaceted Neuropharmacological and Neurobiological Actions
Kohtala, S., & Annala, I. (2025) · Neuromethods · doi:10.1007/978-1-0716-4603-8_2
Ketamine for neuropathic pain: Animal and human studies
Dahan, A., Niesters, M., Sarton, E. Y., & van Velzen, M. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29930-8.00016-3
Neves, G. A. (2009) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Trip killers: Addressing a critical knowledge gap in psychedelic research
O’Mahony, B. W., Harrington, C., Harkin, A., & Lally, N. (2026) · Journal of Psychopharmacology · doi:10.1177/02698811261431056
“…relevant depending on the psychedelic, for example, dopamine 2 receptors at high doses of LSD; sigma-1 receptor in DMT and related tryptamines; and trace amine-asso-ciated receptor 1 in phenylethylamines (De Gregorio et al., 2016a; Fontanilla et al., 2009; Seeman et al., 2005; Xie & Miller, 2008).”
Prise en charge médicamenteuse des patients souffrant de douleur chronique réfractaire
Corriger, A. (2019) · theses.fr (ABES) · doi:10.70675/668e4777zf8d0z4bdcz9780z0f91fedfe2b6
Esketamine Exposure Affects Neurodevelopment and Glutamate‐NMDAR Signaling in Zebrafish Larvae
Wang, J., Huang, S., Lin, T., Fu, Z., Zuo, Z., Chen, Z. F., & He, C. (2026) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.70839 · Cited by 1
Lee, K., Jung, J. H., Lee, J., Lee, J. W., Jeong, C.-H., Kim, E., & Lee, S. (2026) · Current Oncology Reports · doi:10.1007/s11912-026-01849-5
“Additionally, ketamine stabilizes neural excitability via sodium and HCN channels blockade, facilitation of GABA A receptor signaling, and modulation of cholinergic, dopamine D2 receptors [ 61–63], L-type voltage-gated calcium channels [ 63].”
Engel, M. (2014) · Research Online (University of Wollongong)
Metadata
- Authors
- Seeman, P., Ko, F., & Tallerico, T.
- Affiliations
- University of Toronto (CA)
- Corresponding author
- Seeman, P
- ORCID
- Seeman, P
- Venue
- Molecular Psychiatry
- Published
- 2005-04-26
- Volume
- 10
- Issue
- 9
- Pages
- 877-883
- ISSN
- 1359-4184 (ISSN-L)
- 1476-5578
- OpenAlex
- W2024217117
- Cited by
- 200
- References
- 38
- Citations by year
- 2026: 3 · 2025: 7 · 2024: 8 · 2023: 4 · 2022: 4 · 2021: 8 · 2020: 10 · 2019: 8 · 2018: 11 · 2017: 9 · 2016: 5 · 2015: 14 · 2014: 5 · 2013: 9 · 2012: 9
- FWCI
- 8.40
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Molecular Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Keywords
- dopamine D2 receptor, NMDA receptor, phencyclidine, ketamine, LSD, MK-801, psychotomimetics, schizophrenia, receptor binding affinity, dissociation constant
- MeSH terms
- Animals, Cloning, Molecular, Corpus Striatum, Domperidone, Dopamine, Cricetinae, Ketamine, Kinetics, Lysergic Acid Diethylamide, Membrane Glycoproteins, Nerve Tissue Proteins, Phencyclidine, Dizocilpine Maleate, CHO Cells, Receptors, Dopamine D2, Excitatory Amino Acid Antagonists, Membrane Transport Proteins, Dopamine Plasma Membrane Transport Proteins, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.